Shattuck Labs, Inc. (STTK) Company Overview

Shattuck Labs, Inc. is a clinical-stage biotechnology company listed on the Nasdaq Global Select Market as STTK. It has no approved commercial product. Shattuck designs monoclonal and bispecific antibodies that block Death Receptor 3, or DR3, for inflammatory and immune-mediated diseases. Its investor overview describes the lead program, SL-325, as an antagonist antibody intended to block the clinically validated TL1A/DR3 pathway more completely and durably than antibodies that bind TL1A itself.

The business footprint is a focused antibody-development platform

Shattuck’s current pipeline is organized around one biological axis rather than multiple unrelated therapeutic areas. The official pipeline includes SL-325, the clinical-stage DR3 antibody; SL-425, a half-life-extended version; and SL-846, a DR3-by-IL-23 receptor bispecific antibody. Initial clinical development is concentrated in inflammatory bowel disease, especially moderate-to-severe Crohn’s disease, with possible expansion into ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, hidradenitis suppurativa and other inflammatory conditions if the biology translates.

Shattuck is economically a pre-revenue development company, although it occasionally records collaboration or license revenue. FY2025 revenue was $1.0 million from a license transaction, versus $5.7 million from completed collaborations in FY2024. Its model is to raise capital, fund research, generate clinical evidence, and pursue approval, partnership, licensing or another strategic transaction. The 2025 Form 10-K confirms that no product has been approved and no product-sales revenue has been generated.

The cash-conversion cycle runs from financing to clinical milestones

Which spending categories define the model?

The scientific thesis is a receptor-versus-ligand choice. TL1A is an inflammatory ligand, while DR3 is its sole known signaling receptor. Most competing programs bind soluble TL1A; Shattuck binds DR3 on immune cells. The company argues that DR3 is more abundant and stable than transient TL1A expression, potentially enabling more complete blockade. Its science page says membrane-bound DR3 should avoid the large soluble immune complexes associated with anti-TL1A antibodies.

What did the Phase 1 trial establish?

The June 8, 2026 update moved SL-325 into human pharmacology. The Phase 1 trial enrolled 72 healthy participants in six single-dose and three multiple-dose cohorts. Doses ranged from 0.1 to 30.0 mg/kg and 1 to 10 mg/kg, respectively. The company’s June 2026 Form 8-K reported complete DR3 occupancy at 0.1 mg/kg and above, inhibition of TL1A binding for more than 10 weeks, and modeled blockade beyond three months at doses above 1 mg/kg.

These findings do not prove Crohn’s efficacy; healthy-volunteer receptor occupancy is only a pharmacologic bridge. Still, low ADA, proportional exposure, no DR3 agonism and favorable safety support the next experiment. RECEPTIVE-CD1 is designed for 174 patients randomized 1:1:1 to two doses or placebo, with 12-week induction and 40-week maintenance. Its primary endpoint is week-12 endoscopic response, with clinical remission as a key secondary endpoint.

For the quarter ended March 31, 2026, Shattuck remained pre-revenue and used $13.4 million of operating cash as SL-325 spending increased. The Q1 2026 Form 10-Q reported $90.4 million of cash, $6.3 million of liabilities and $95.8 million of equity. Later warrant exercises and the June offering added liquidity.

Q1 2026 confirms rising clinical investment

The pivot materially lowered FY2025 costs: R&D fell 47.5% to $35.3 million from $67.2 million in FY2024, G&A declined 9.7% to $17.2 million, and operating cash use improved to $39.9 million from $60.5 million. Phase 2 development should raise R&D again.

Shattuck’s history matters because the present company is not simply a linear continuation of its original oncology platform. It is the result of a strategic reset from fusion-protein oncology programs toward DR3-focused immunology. That reset reduced costs, changed the investor base and concentrated the company’s future around one mechanism.

1. 2016
   Shattuck was incorporated and began building protein-engineering capabilities around TNF receptor biology.
2. 2020
   The company completed its initial public offering and began trading publicly, creating access to equity capital for clinical development.
3. 2020–2023
   SL-172154 advanced through early oncology studies, establishing clinical-operating capabilities but also exposing the risk of translating interim response signals into durable outcomes.
4. October 2024
   Shattuck discontinued SL-172154 after promising interim remission rates did not translate into improved overall survival. This was the decisive portfolio reset.
5. August 2025
   The FDA allowed the SL-325 IND to proceed, and an institutional private placement funded the DR3 strategy through substantial warrant-linked capital.
6. Q4 2025–Q2 2026
   The 72-participant Phase 1 study enrolled and reported favorable safety, target-occupancy and immunogenicity findings.
7. Q3 2026 planned
   RECEPTIVE-CD1 is expected to begin, moving the company into the efficacy phase of its current strategy.

Shattuck competes in a crowded immunology market already served by anti-TNF, anti-integrin, anti-IL-12/23 and anti-IL-23 drugs. More directly, it faces a fast-moving TL1A class. The 2025 filing names duvakitug, ABBV-701/FG-M701, afimkibart, SPY002, SPY072, tulisokibart and XmAb942. Their sponsors—Teva, AbbVie/FutureGen, Roche, Spyre, Merck and Xencor—generally have much greater clinical, manufacturing and commercial resources.

The differentiation claim is first-in-class DR3 blockade, not market leadership

Does Shattuck have a moat?

The potential moat is a combination of protein-engineering know-how, DR3-specific intellectual property, early clinical experience and a bispecific pipeline that reuses the same target biology. It is not yet a durable commercial moat. Patents can be challenged, competitors can design around claims, and superior Phase 3 data from anti-TL1A programs could set a high efficacy benchmark before SL-325 reaches pivotal development.

At March 31, 2026, Shattuck had $90.4 million in cash versus $78.1 million of cash and investments at December 31, 2025. Total liabilities were $6.3 million, including $4.2 million current liabilities. Leverage was modest; the key balance-sheet issue was runway against Phase 2b cost.

Warrant exercises and the public offering materially changed liquidity

On June 9, Shattuck reported exercise notices for about 50.6 million warrants, roughly 96% of those issued in August 2025. Expected gross proceeds were $54.9 million: $5.6 million received by March 31 and $49.3 million afterward. The warrant-exercise update said cash plus proceeds should fund operations into 2029.

The June offering added 10.9 million common shares, pre-funded warrants for 7.9 million shares and an underwriter option for another 2.8 million shares, near $4.00 per security. The offering Form 8-K therefore signals both lower financing risk and substantial per-share dilution.

The investor base became heavily specialized after the August 2025 private placement. The 2026 proxy statement listed Prosight, Redmile, Adage, OrbiMed and T. Rowe Price as major holders. Its snapshot was dated March 15, 2026, before the June warrant exercises and offering, so the percentages below are a pre-financing governance snapshot rather than current economic stakes.

Specialist institutions supplied both capital and credibility

Governance separates scientific leadership from board oversight

Co-founder Taylor Schreiber has served as chief executive since January 2020 and remains a director. The seven-member 2026 board included six Nasdaq-independent directors, with George Golumbeski as independent chairman. Audit, compensation, and nominating and governance committees were fully independent. Each common share carries one vote, with no dual-class founder control.

The opportunity is unusually asymmetric. A successful Phase 2b study could validate the first clinical DR3-blocking antibody and position SL-325 against the TL1A class. Failure could impair both the lead asset and the biology reused by SL-425 and SL-846. The filing also highlights dependence on clinical sites, contract manufacturers, intellectual property, patient enrollment and regulatory approval.

The main upside is proof that receptor blockade improves the class

The biggest risks connect directly to clinical and financial line items

Shattuck cannot be valued like a mature company because current revenue is incidental and its lead asset has not shown patient efficacy. A research model needs a probability-weighted pipeline framework: define Phase 2, Phase 3, regulatory and commercial success probabilities; estimate addressable patients, pricing and penetration; then subtract future development, commercialization and dilution costs.